...
首页> 外文期刊>World Journal of Gastroenterology >Lymphatic metastasis and nm23H_1 genetic instability in Chinese colon cancer patients
【24h】

Lymphatic metastasis and nm23H_1 genetic instability in Chinese colon cancer patients

机译:中国结肠癌患者的淋巴转移和nm23H_1基因不稳定

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To investigate the pathogenic mechanism of colon cancer at the molecular level and to elucidate the relationship between intercellular adhesion molecule-1 (ICAM-1) and nm23H_1 genes and Chinese patients with colon cancer. METHODS: DNA was extracted from paraffin-embedded materials. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) was used to analyze MSI and LOH. Expression of ICAM-1 was detected by Envision immuno-histochemistry. Experimental results were analyzed with Leica-Qwin computer imaging techniques and SPSS software of statistics. RESULTS: ICAM-1 expression of lymphatic endothelium was negative in normal colon and positive in colon cancer respectively. The number of lymphatics positive for ICAM-1 was gradually increased with degree of cancer invasion (P< 0.01). In the group with metastasis of colon cancer, the number of lymphatics positive for ICAM-1 in lymph nodes was more than that in the group with no metastasis (P< 0.01). The frequency of MSI, LOH and nm23H_1 protein was 26.67%, 20.00% and 53.33% in colon cancer, respectively. In TNM staging, MSI (43.75%) and nm23H_1 protein (81.25%) in stagesⅠ+ Ⅱ were detected more easily than the corresponding indexes (MSI: 7.14%, P< 0.05 and nm23H_1: 21.43%, P< 0.01) in stages Ⅲ+ Ⅳ. By comparison, the frequency of LOH (35.71%) in stages Ⅲ+ Ⅳ was more than that of LOH (6.25%, P< 0.05) in stages Ⅰ+ Ⅱ. LOH exhibited a rising trend along with the Duke's staging. nm23H_1 protein in the group of tubular adenocarcinoma (60.00%) was higher expressed than that in the group of mucoid adenocarcinoma (20.00%) (P< 0.01), and exhibited a rising trend with the differentiation degrees of tubular adenocarcinoma. nm23H_1 protein in MSI positive group was higher expressed (75%) than that in MSI negative group (45.45%, P< 0.05). CONCLUSION: The expression of ICAM-1 in lymphatic vessels is beneficial to the judgement of the invasion and metastasis ability of colon cancer and the anti-tumor immunity function, and shows an important clinical significance in predicting lymphatic metastasis of colon cancer. MSI and LOH may separately control the development of sporadic colon cancer with different pathways. LOH mostly arises in the late period of sporadic cofon cancer and endows a high aggressive and poor prognostic phenotype. By compassion, MSI may be an early period molecule marker for sporadic colon cancer, enhanced expression of nm23H_1 protein can effectively inhibit colon cancer metastasis and improve prognosis of sporadic colon cancer patients.
机译:目的:从分子水平探讨结肠癌的致病机制,阐明细胞间黏附分子-1(ICAM-1)和nm23H_1基因与中国结肠癌患者之间的关系。方法:从石蜡包埋的材料中提取DNA。用聚合酶链反应-单链构象多态性(PCR-SSCP)分析MSI和LOH。通过Envision免疫组织化学检测ICAM-1的表达。实验结果用Leica-Qwin计算机成像技术和SPSS统计软件进行分析。结果:淋巴管内皮细胞ICAM-1表达在正常结肠中为阴性,在结肠癌中为阳性。 ICAM-1阳性的淋巴管数目随着癌症侵袭程度的增加而逐渐增加(P <0.01)。结肠癌转移组中,淋巴结中ICAM-1阳性的淋巴管数目多于无转移组(P <0.01)。在结肠癌中,MSI,LOH和nm23H_1蛋白的频率分别为26.67%,20.00%和53.33%。在TNM分期中,Ⅰ+Ⅱ期的MSI(43.75%)和nm23H_1蛋白(81.25%)比Ⅲ期相应的指标(MSI:7.14%,P <0.05; nm23H_1:21.43%,P <0.01)更容易被检测到。 +Ⅳ。相比之下,Ⅲ+Ⅳ期的LOH频率(35.71%)要大于Ⅰ+Ⅱ期的LOH频率(6.25%,P <0.05)。随着公爵的演出,乐活呈现出上升的趋势。肾小管腺癌组(23.0%)中的nm23H_1蛋白表达高于粘液腺癌(20.00%)组(P <0.01),并随肾小管腺癌的分化程度呈上升趋势。 MSI阳性组的nm23H_1蛋白表达较高(75%),MSI阴性组的表达较高(45.45%,P <0.05)。结论:ICAM-1在淋巴管中的表达有助于判断结肠癌的侵袭和转移能力以及抗肿瘤免疫功能,在预测结肠癌的淋巴转移中具有重要的临床意义。 MSI和LOH可能通过不同途径分别控制散发性结肠癌的发展。 LOH多发于散发性结肠癌的晚期,并具有高侵袭性和不良的预后表型。出于同情,MSI可能是散发性结肠癌的早期分子标志物,nm23H_1蛋白的表达增强可以有效抑制散发性结肠癌患者的转移并改善预后。

著录项

  • 来源
    《World Journal of Gastroenterology》 |2004年第19期|p.2800-2804|共5页
  • 作者

    Zhi-Hong Su; Ji-Cheng Li;

  • 作者单位

    Department of Histology and Embryology, Zhejiang University Medical College, Hangzhou 310031, Zhejiang Province, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号